ARCHIVES

FDA Committee Okays High Dose Methotrexate, Mitxantrone In ANL; reverse Breast Cancer Vote

This article is from The Cancer Letter archive.

Vol. 13 No. 48 | December 11, 1987

Download PDF Visit The Full Archive

Related Articles

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Federal AIDS Funds Tp $2 Bil.; Term Proposed For NIH Director

October 19, 1990

UPCI Recruits Shin To Lead Head & Neck Cancer Program.

April 27, 2001

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

April 16, 1999

Congress Passes NIH Reauthorization.

December 15, 2006

FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.

March 23, 2001